E Watertown, Massachusetts Clinical Trials

A listing of E Watertown, Massachusetts clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1958 clinical trials
featured
A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

vitiligo
TUFTS MEDICAL CENTER
 (6.4 away) Contact site
  • 9156 views
  • 15 Dec, 2020
  • +14 other locations
featured
Fox Insight - Online Parkinson's Health and Genetic Study

Fox Insight is an online study gathering health information from tens of thousands of people with and without Parkinson’s disease.  Study participation does not require any travel and all you need is an internet connection to start today at www.foxinsight.org Fox Insight volunteers are invited to take part in virtual …

www.foxinsight.org
 (3.7 away) Contact site
  • 3557 views
  • 29 Mar, 2021
  • +333 other locations
featured
An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Massachusetts General Hospital
 (6.0 away) Contact site
  • 780 views
  • 25 Mar, 2021
  • +29 other locations
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Research Center (DNU)
 (9.2 away) Contact site
  • 1940 views
  • 25 Mar, 2021
  • +106 other locations
featured
GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

graft-versus-host disease
Beth Israel Deaconess Medical Center
 (4.4 away) Contact site
  • 1462 views
  • 08 Dec, 2020
  • +10 other locations
featured
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (516-003)

This is a study involving an investigational (experimental) drug called sitravatinib, given in combination with the immunotherapy nivolumab (also known as OPDIVO®).  Sitravatinib is designed to block specific proteins that are thought to cause tumors to grow and to prevent growth of new blood vessels that help cancer tumors to …

nivolumab
advanced urothelial carcinoma
metastatic urothelial carcinoma
tumor cells
urothelial carcinoma
Dana Farber Cancer Institute
 (4.4 away) Contact site
  • 80 views
  • 02 Jun, 2021
  • +35 other locations
featured
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

advanced solid tumor
malignant solid tumor
solid tumor
Mirati Research Site
 (4.5 away) Contact site
  • 405 views
  • 08 Jul, 2021
  • +72 other locations
featured
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Characterize the safety and tolerability, and evaluate Pharmacokinetics of MRTX849 in combination with TNO155 in patients with advanced solid tumor malignancies with KRAS G12C mutation. MRTX849 is an orally available small molecute inhibitor of KRASG12C. TNO155 is a selective, orally bioavailable allosteric inhibitor of wild type SHP2.

advanced solid tumor
solid tumors
solid tumor
malignant solid tumor
Dana Farber
 (4.4 away) Contact site
  • 114 views
  • 19 Feb, 2021
  • +9 other locations
featured
Caregiver-Provided Life Review for Persons with Dementia in Care Facilities

Five percent of community‐dwelling older Americans experience depression. The rate is higher among persons with dementia (30%). One in 10 older adults (5.6 million) had Alzheimer’s dementia in 2019 and 70% are cared for by their families. This public health issue will worsen as the aging baby boomers grow from …

depression
dementia
Online253
 (4.1 away) Contact site
  • 208 views
  • 07 Jul, 2021
  • +252 other locations
featured
[Online] The Neureka Project

The Neureka Project aims to develop new ways of detecting disorders of the brain early. From mental health conditions to dementia, we want to find out who is at risk and why, so we can develop preventative interventions that can be used the world over. To do this, we are taking …

[Online] The Neureka Project
 (3.7 away) Contact site
  • 0 views
  • 29 Apr, 2021
  • +240 other locations